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Introduction: It is frequent for news items to lead to a short lived temporary increase in interest in a particular
health related service, however it is rare for this to have a long lasting effect. In 2013, in the UK in particular, there
has been unprecedented publicity in hereditary breast cancer, with Angelina Jolie’s decision to have genetic testing
for the BRCA1 gene and subsequently undergo risk reducing mastectomy (RRM), and a pre-release of the NICE
guidelines on familial breast cancer in January and their final release on 26th June. The release of NICE guidelines
created a lot of publicity over the potential for use of chemoprevention using tamoxifen or raloxifene. However, the
longest lasting news story was the release of details of film actress Angelina Jolie’s genetic test and surgery.
Methods: To assess the potential effects of the ‘Angelina Jolie’ effect, referral data specific to breast cancer family
history was obtained from around the UK for the years 2012 and 2013. A consortium of over 30 breast cancer
family history clinics that have contributed to two research studies on early breast surveillance were asked to
participate as well as 10 genetics centres. Monthly referrals to each service were collated and increases from 2012
to 2013 assessed.
Results: Data from 12 family history clinics and 9 regional genetics services showed a rise in referrals from May
2013 onwards. Referrals were nearly 2.5 fold in June and July 2013 from 1,981 (2012) to 4,847 (2013) and remained
at around two-fold to October 2013. Demand for BRCA1/2 testing almost doubled and there were also many more
enquiries for risk reducing mastectomy. Internal review shows that there was no increase in inappropriate referrals.
Conclusions: The Angelina Jolie effect has been long lasting and global, and appears to have increased referrals to
centres appropriately.Introduction
It is frequent for news items to lead to a short-lived
temporary increase in interest in a particular health-
related service. It is rare for this to have a long-lasting
effect. In 2013 in the UK in particular there has been un-
precedented publicity on hereditary breast cancer with a
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unless otherwise stated.Excellence (NICE) guidelines on familial breast cancer in
January 2013 and their final release on 26 June. The
release of NICE guidelines created much publicity over
the potential for use of chemoprevention [1] using tam-
oxifen or raloxifene. However, the longest-lasting news
story was the release of details surrounding the film
actress Angelina Jolie’s decision to have genetic testing for
the BRCA1 gene and subsequently undergo risk-reducing
mastectomy (RRM). Unusually this story lasted several
weeks in the newspapers and on TV and radio, and longer
in magazines. Indeed the story resurfaced with news items
on the BBC in December. The so-called Angelina Jolie
effect prompted publicity across the English-speakingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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breast screening, hereditary breast cancer clinics and
genetics services in the USA, Canada, Australia, New
Zealand and the UK [2-6]. An article in Australia con-
firmed a tripling in breast cancer referrals for genetics,
family cancer centres in Victoria, New South Wales and
South Australia, which had a combined 90 referrals a
week in the six weeks before Ms Jolie’s announcement,
which doubled and then tripled to a peak of 280 refer-
rals in the weeks after. The article from November some
6 months after the Jolie story broke on 14 May, showed
that referrals had since settled at about 190 a week,
demonstrating the Angelina effect was ongoing. There
was some initial press criticism of Ms Jolie’s decision to
undergo RRM, but this abated to a large extent when it
was announced 15 days after the initial news story that
her aunt had died of breast cancer (the initial stories
only mentioned ovarian cancer in her mother). Calls to
the Hereditary Breast Cancer Helpline in the UK have
increased 10-fold and still remained high in January
2014 [7]. The helpline states that no other news story
has had such an effect [7]. All the familial breast cancer
clinics we have contacted in the UK have noted increases
in referrals that they attribute to the story.
Familial breast cancer services
Breast cancer family history clinics (FHCs) have existed
in the UK since 1986 [8,9]. Each service saw an initial
exponential rise in referrals (Figure 1a), which was to
some extent caused by a new service meeting an unful-
filled need. Most services then saw a plateau in referrals.
In the UK referrals of women with a family history of
breast cancer have largely been triaged since the mid
1990s with average-risk women being reassured in pri-
mary care and moderate-risk women aged <50 years of
age potentially gaining access to additional surveillance
mammography at local FHCs [10], with those at high
risk (>1 in 4 lifetime risk) gaining access to genetics ser-
vices and potentially testing for BRCA1/2 mutations
[10]. These guidelines were eventually enshrined into
NICE guidance with the publication of the first guideline
on familial breast cancer in 2004 [11]. The most recent
guidance was summarised in this journal recently and
reduced the threshold for genetic testing for BRCA1/2
mutations to 10% [12].
Methods
Assessment of the Angelina Jolie effect
To assess the potential effects of the Angelina Jolie
effect, referral data specific to breast cancer family history
was obtained from around the UK for the years 2012 and
2013. A consortium of 34 breast cancer FHCs that have
contributed to two research studies on early breast sur-
veillance [13,14] were asked to participate. Likewise 10/19of the Regional Genetics Centres (RGCs) that were ap-
proached had cancer-specific referral data (one of the
centres could not separate breast from other cancers) and
were invited (Table 1). Monthly referrals to each service
were collated and increases from 2012 to 2013 assessed.
In Manchester the appropriateness of referrals against
local guidelines was assessed. This study was an audit and
did not require ethical approval.
Results
Referral patterns for the 21 centres (12 FHCs and 9
RGCs) that participated are shown in Figure 1b and
Table 1. Centres that did not supply data either did not
have this available or were unable to collate the data.
The data were available across Wales through the All
Wales Genetics Service, covering seven Welsh regions
and a population of around 3.1 million people. Further
data were available from the Genesis Prevention Centre
in Manchester and FHCs in Crewe, Bath, The Royal
Marsden and St Bartholomew’s London, Derby, Coventry,
Nottingham, Grantham, City Hospital Birmingham,
Londonderry and Edinburgh. RGC data were available
from Aberdeen, Leicester, Bristol, Guy’s and North-
West Thames, London, Nottingham, Birmingham and
Southampton.
Although referral rates were 17% higher in January to
April 2013, the rates clearly rose further in May and
June before an effect from the release of the full NICE
guidance would have been seen. The nearly 50% increase
in May reflects that only half the month would have
been available to women to see their general practi-
tioners (GPs) for a referral. Rates were around 2.5-fold
higher in June and July from 1,981 (2012) to 4,847 (2013)
and around 2-fold higher still in August through to
October. The referral rates then settled back to 32%
higher in November/December.
The extensive publicity when the updated NICE clin-
ical guideline was published focused largely on chemo-
prevention and resulted in only a marginal increase in
referrals relating to use of tamoxifen or raloxifene. In
contrast, all participating centres were conscious of a
more significant increase in women attending referring
to the Angelina Jolie story and further, noted women
seen in the past seeking updated advice on testing and
risk-reducing surgery. Areas with very strong FHCs saw
less pronounced effects in their RGCs. Altogether refer-
rals rose from 12,142 in 2012 to 19,751 in 2013. Data from
the Manchester FHC showed that 451/678 (Figure 1b,
66.5%) of referrals in 2013 were eligible to be seen after a
questionnaire was received compared to similar propor-
tions in the two previous years 265/421 (63%) in 2012 and
304/455 (67%) in 2011. The effects on referrals for genetic
testing are likely to be confounded by the change in NICE
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Figure 1 Breast cancer family history (FH) referrals. (a) Breast cancer FH referrals to the South Manchester family history clinic (FHC) showing
exponential rise in referrals in early 1990s and second rise in 2013. (b) Breast cancer FH referrals to 21 centres in 2012/2013 by month. 12 FHCs
and 9 UK Genetic services.
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Leicester, Nottingham, Wales, Southampton, NW Thames,
Guys, East of Scotland) we saw a rise from 538 full
BRCA1/2 tests in July 2012 to December 2012 compared
to 967 (80% increase) for the same period in 2013, despite
no extra funding being available for testing. The effects on
referral for RRM were also assessable in Manchester for
the same 6-month periods. As it takes an average of
8 months for women to go through two genetic counsel-
ling sessions a psychological assessment and two surgical
sessions before surgery is possible in women unaffected
with breast cancer [12,14], we assessed the rates of referral
for psychological assessment in the same study periods
(July to December). There were 13 referrals in 2012 com-
pared to 24 in 2013. All services have found the increase
in demand through referrals and increased genetic testing
difficult as there is no mechanism for additional funding
in the UK Health service to cover such eventualities.Controls
We were also able to assess familial colorectal cancer or
other non-breast cancer referrals for the same two-year
period from six RGCs as a comparison. There was no
substantial rise from 2012 to 2013 and in particular no
trend around the Jolie news story or NICE guidance on
familial breast cancer.
Discussion
Publications of the Angelina Jolie effect
A survey carried out in the USA [15] found that
although 75% of Americans were aware of Angelina Jolie’s
double mastectomy, fewer than 10% of respondents had
the information necessary to accurately interpret her risk
of developing cancer relative to a woman unaffected by
the BRCA gene mutation. Awareness of the Angelina Jolie
story was not associated with improved understanding.
However, 9% of women were motivated to do something
Table 1 National Health Service Regional Genetics Centres and family history clinics, their potential catchment area and
referrals in 2012/2013
Centre Type Population coverage Number referred 2012 Number referred 2013
Guys Hospital, SW Thames, London Regional Genetics Centre 4.9 million 1,762 2,727
Birmingham Regional Genetics Centre 5.5 million 1,993 3,421
Southampton Regional Genetics Centre Approximately 3 million 735 1,032
Leicester Regional Genetics Centre Approximately 2 million 331 443
Aberdeen, Scotland Regional Genetics Centre Approximately 1 million 387 742
Bristol Regional Genetics Centre 2.46 million 919 1,462
All Wales Genetics Service National Genetics Centre 3.1 million 1,462 2,727
Nottingham Regional Genetics Centre 2.2 million 1,015 1,252
Northwick Park, London Regional Genetics Centre 3.6 million 760 1,902
Genesis Prevention Centre, Manchester Family history clinic 4.5 million (for high risk) 367 678
Royal Marsden, London Family history clinic <1 million 255 320
Nottingham Family history clinic ~1 million 554 739
Bath Family history clinic <1 million 166 278
St Bartholomew’s, London Family history clinic <1 million 538 627
Royal Derby Hospital Family history clinic <1 million 285 511
United Lincolnshire Hospitals NHS Trust Family history clinic <0.5 million 33 53
Sandwell Hospital, Birmingham Family history clinic <1 million 78 48
Edinburgh, Scotland Family history clinic <1 million 73 160
Leighton Hospital, Crewe Family history clinic <1 million 121 172
Coventry Family history clinic <0.5 million 178 192
Altnagelvin Hospital, N Ireland Family history clinic <1 million 130 202
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mogram or seeing a genetic counselor. The increased level
of appropriate referrals in the UK may reflect a similar
effect. The authors concluded that although celebrities
can bring heightened awareness to health issues, there is a
need for these messages to be accompanied by more
purposeful communication efforts to assist the public un-
derstanding. There is no evidence from the current study
that the story led to inappropriate referrals although it is
possible that primary care physicians had to see many
women who were unnecessarily worried about breast can-
cer, or observed an increased need for BRCA testing in
the months following the revelation. It is likely that the
release of NICE guidance with the attendant publicity
may have made it easier to deal with the onslaught of
enquiries about familial breast cancer. It is also likely
that given the high level of appropriate referrals re-
ceived in clinics, that the triage process set up in the
1990s is still effective today. Nevertheless, the high
number of appropriate referrals means that many women
will have been either unaware of the relevance of their
family history or hiding concerns such that so many newly
identified women and families could come forward in a
7-month period.Similar stories
A similar effect on health service activity happened six
years ago, when a reality TV star Jade Goody was
diagnosed with and then died of cervical cancer [16].
There are parallels in the media coverage around this
UK story as there were multiple news items over several
months. A study, in the Journal of Medical Screening,
discussed the effect of her diagnosis and death on
cervical screening attendance [17]. It showed that more
than 400,000 extra women were screened in England
between mid 2008 and mid 2009 - the period during
which Jade Goody was diagnosed with and died of
cervical cancer.
More women of all ages were screened, though the in-
crease was greater for women aged <50 years. In the 25 to
29 years age-group, an estimated 31,000 extra women
were screened in 5 months between autumn 2008 and
spring 2009. It appeared that women closest to Jade
Goody’s age or circumstances were those most affected by
her experience [18]. Data from 890 participants showed
that 40% of women felt Goody’s story had influenced their
decisions about cervical screening. Younger women (aged
26 to 35 years) were more likely to have been influenced
by Goody’s story than older women [18].
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the USA after Katie Couric’s colorectal cancer awareness
campaign on colonoscopy rates on the Today Show in
March 2000 [19]. The number of colonoscopies perfor-
med per month after Ms Couric’s campaign increased
significantly (15.0 per month before and 18.1 per month
after the campaign; P <0.001). After adjusting for temporal
trends, a significantly higher post-campaign colonoscopy
rate was sustained for 9 months [19].
Although there was concern that the increase in
attendance might have been from the so-called worried-
well coming back for an early repeat screen, the research
found that the opposite was true. A higher proportion
was from women who were late for their test, rather
than those who were coming back early [18]. In the 25
to 49 years age group, for example, 82,000 (28%) women
had not been tested for five years or longer, while only
7,500 (8%) were coming back early, having already been
screened in the past three years. The increase in appro-
priate use of health service resources from the Jade
Goody effect appears similar to that of the Angelina Jolie
effect. Other examples of notable women increasing or
changing the use of health resources include a 40%
increase in breast screening in Australia with the news
around Kylie Minogue’s diagnosis [20], and a 6-month
25% increase in mastectomy for breast cancer after
Nancy Reagan’s decision not to have breast-conserving
surgery in 1987 [21]. All these stories, including the
current one, show that health news around high profile
individuals can have a sustained effect for at least 6 months
in influencing the uptake of healthcare. We have shown
that for Angelina Jolie the effect has been UK-wide as
well as the reported global effects [2-7]. The increased
awareness of familial cancer in the community alongside
improvements in genetic testing, screening and preven-
tative strategies, provides funding challenges for clinical
genetic services and commissioners.
There are some limitations in the descriptive nature of
the present study and ideally a prospective study imme-
diately investigating motivations for referral would likely
have added support to the findings. Future studies might
anticipate a celebrity providing publicity in a healthcare
area and design studies to gain a more in-depth under-
standing of referral patterns.
Conclusions
Angelina Jolie stating she has a BRCA1 mutation and
going on to have a RRM is likely to have had a bigger
impact than other celebrity announcements possibly due
to her glamorous image and relationship to Brad Pitt.
This may have lessened patients’ fears about a loss of
sexual identity post preventative surgery and encouraged
those who had not previously engaged with health
services to consider genetic testing. It is not currentlystandard practice to proactively take a family history
of cancer in primary care [11]. Hence there is an onus on
at-risk relatives to be aware of their family history and
request screening or risk-reducing strategies, resulting in
possible inequality of access. Education of the general
public is therefore extremely important in increasing
awareness of, and improving access to, familial cancer ser-
vices. This is particularly relevant due to the NICE guid-
ance update increasing access to genetic testing, screening
and chemoprevention [12].
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